Revelation Biosciences Reports $3.0 Million Net Loss and Increased Operating Expenses for Q1 2026

Revelation Biosciences, Inc. reported a net loss of $3.0 million for the three months ended March 31, 2026, compared to a net loss of $2.1 million for the same period in 2025. The company's total operating expenses increased to $3.1 million from $2.1 million year-over-year, driven primarily by higher research and development costs, which rose to $1.4 million from $0.9 million. General and administrative expenses also saw an increase, climbing to $1.7 million from $1.2 million. The company has not generated any revenue since its inception and continues to face significant operating losses, with an accumulated deficit of $52.4 million as of March 31, 2026.

In terms of financial position, Revelation's total assets increased to $15.0 million as of March 31, 2026, up from $11.6 million at the end of 2025. This growth was primarily attributed to an increase in cash and cash equivalents, which rose to $14.1 million from $10.7 million, following a successful warrant inducement exercise that generated approximately $6.7 million in net proceeds. The company’s total liabilities decreased to $2.1 million from $2.7 million, reflecting a reduction in accrued expenses and operating lease liabilities.

Strategically, Revelation has made significant moves to bolster its financial standing and operational capabilities. The company executed a 1-for-4 reverse stock split on January 28, 2026, aimed at improving its stock price and compliance with Nasdaq listing requirements. Additionally, the company has been actively engaging in warrant inducement offers, which have successfully raised capital. The Class I Warrant Inducement, completed in January 2026, involved the exercise of 2.1 million warrants at a reduced price, further enhancing the company's liquidity.

Operationally, Revelation is focused on advancing its product candidates, GEM-AKI and GEM-CKD, which are in development for acute and chronic kidney diseases, respectively. The company anticipates that its research and development expenses will continue to rise as it progresses through clinical studies and regulatory processes. However, the company has expressed concerns regarding its ability to sustain operations beyond one year without additional funding, indicating a need for further capital raises through equity or debt financing.

Looking ahead, Revelation Biosciences acknowledges the uncertainty surrounding its future revenue generation, as it does not expect to achieve profitability until it successfully completes product development and obtains regulatory approvals. The company plans to continue seeking additional funding to support its ongoing research and development efforts, while also managing the risks associated with its operational and financial strategies.